Bone morphogenetic protein -4 and -5 in pancreatic cancer-Novel bidirectional players

Experimental Cell Research

Volumn 317, Issue 15, 2011, Pages 2136-2146

  Virtanen, Siru ^a   Alarmo, Emma Leena ^a   Sandström, Saana ^a   Ampuja, Minna ^a   Kallioniemi, Anne ^a  

^a UNIVERSITY OF TAMPERE   (Finland)

Author keywords

Bone morphogenetic protein; Invasion; Migration; Pancreatic cancer; Proliferation

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 5; BONE MORPHOGENETIC PROTEIN 6; BONE MORPHOGENETIC PROTEIN RECEPTOR; LIGAND; SMAD PROTEIN;

ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL MIGRATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

EID: 79960834796     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2011.06.001     Document Type: Article

References (49)

1. Reddi A. Bone morphogenetic proteins: an unconventional approach to isolation of first mammalian morphogens. Cytokine Growth Factor Rev. 1997, 8:11-20.
2. Wozney J. Overview of bone morphogenetic proteins. Spine (Phila Pa 1976) 2002, 27:S2-S8.
3. Kawabata M., Imamura T., Miyazono K. Signal transduction by bone morphogenetic proteins. Cytokine Growth Factor Rev. 1998, 9:49-61.
4. Koenig B.B., Cook J.S., Wolsing D.H., Ting J., Tiesman J.P., Correa P.E., Olson C.A., Pecquet A.L., Ventura F., Grant R.A., et al. Characterization and cloning of a receptor for BMP-2 and BMP-4 from NIH 3T3 cells. Mol. Cell. Biol. 1994, 14:5961-5974.
5. Heldin C.H., Miyazono K., ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997, 390:465-471.
6. Kretzschmar M., Doody J., Massague J. Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1. Nature 1997, 389:618-622.
7. Nishimura R., Kato Y., Chen D., Harris S.E., Mundy G.R., Yoneda T. Smad5 and DPC4 are key molecules in mediating BMP-2-induced osteoblastic differentiation of the pluripotent mesenchymal precursor cell line C2C12. J. Biol. Chem. 1998, 273:1872-1879.
8. Kawai S., Faucheu C., Gallea S., Spinella-Jaegle S., Atfi A., Baron R., Roman S.R. Mouse smad8 phosphorylation downstream of BMP receptors ALK-2, ALK-3, and ALK-6 induces its association with Smad4 and transcriptional activity. Biochem. Biophys. Res. Commun. 2000, 271:682-687.
9. Lagna G., Hata A., Hemmati-Brivanlou A., Massague J. Partnership between DPC4 and SMAD proteins in TGF-beta signalling pathways. Nature 1996, 383:832-836.
10. Derynck R., Zhang Y. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003, 425:577-584.
11. Nohe A., Keating E., Knaus P., Petersen N. Signal transduction of bone morphogenetic protein receptors. Cell. Signal. 2004, 16:291-299.
12. Javelaud D., Mauviel A. Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-beta: implications for carcinogenesis. Oncogene 2005, 24:5742-5750.
13. Chen H.L., Panchision D.M. Concise review: bone morphogenetic protein pleiotropism in neural stem cells and their derivatives-alternative pathways, convergent signals. Stem Cells 2007, 25:63-68.
14. Hogan B.L.M. Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Gene Dev. 1996, 10:1580-1594.
15. Thawani J.P., Wang A.C., Than K.D., Lin C.Y., La Marca F., Park P. Bone morphogenetic proteins and cancer: review of the literature. Neurosurgery 2010, 66:233-246. (discussion 246).
16. Singh A., Morris R.J. The Yin and Yang of bone morphogenetic proteins in cancer. Cytokine Growth Factor Rev. 2010, 21:299-313.
17. Alarmo E.-L., Kallioniemi A. Bone morphogenetic proteins in breast cancer: dual role in tumourigenesis?. Endocr. Relat. Cancer 2010, 17:R123-R139.
18. Howe J., Bair J., Sayed M., Anderson M., Mitros F., Petersen G., Velculescu V., Traverso G., Vogelstein B. Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat. Genet. 2001, 28:184-187.
19. Zhou X., Woodford-Richens K., Lehtonen R., Kurose K., Aldred M., Hampel H., Launonen V., Virta S., Pilarski R., Salovaara R., Bodmer W., Conrad B., Dunlop M., Hodgson S., Iwama T., Järvinen H., Kellokumpu I., Kim J., Leggett B., Markie D., Mecklin J., Neale K., Phillips R., Piris J., Rozen P., Houlston R., Aaltonen L., Tomlinson I., Eng C. Germline mutations in BMPR1A/ALK3 cause a subset of cases of juvenile polyposis syndrome and of Cowden and Bannayan-Riley-Ruvalcaba syndromes. Am. J. Hum. Genet. 2001, 69:704-711.
20. Corey E., Vessella R.L. Bone morphogenetic proteins and prostate cancer: evolving complexities. J. Urol. 2007, 178:750-751.
21. Keller E.T., Zhang J., Cooper C.R., Smith P.C., McCauley L.K., Pienta K.J., Taichman R.S. Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastasis Rev. 2001, 20:333-349.
22. Logothetis C.J., Lin S.H. Osteoblasts in prostate cancer metastasis to bone. Nat. Rev. Cancer 2005, 5:21-28.
23. Kodach L.L., Bleuming S.A., Musler A.R., Peppelenbosch M.P., Hommes D.W., van den Brink G.R., van Noesel C.J., Offerhaus G.J., Hardwick J.C. The bone morphogenetic protein pathway is active in human colon adenomas and inactivated in colorectal cancer. Cancer 2008, 112:300-306.
24. Alarmo E.-L., Parssinen J., Ketolainen J.M., Savinainen K., Karhu R., Kallioniemi A. BMP7 influences proliferation, migration, and invasion of breast cancer cells. Cancer Lett. 2009, 275:35-43.
25. Katsuno Y., Hanyu A., Kanda H., Ishikawa Y., Akiyama F., Iwase T., Ogata E., Ehata S., Miyazono K., Imamura T. Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway. Oncogene 2008, 27:6322-6333.
26. Feeley B.T., Krenek L., Liu N., Hsu W.K., Gamradt S.C., Schwarz E.M., Huard J., Lieberman J.R. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. Bone 2006, 38:154-166.
27. Kleeff J., Maruyama H., Ishiwata T., Sawhney H., Friess H., Buchler M.W., Korc M. Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo. Gastroenterology 1999, 116:1202-1216.
28. Gordon K.J., Kirkbride K.C., How T., Blobe G.C. Bone morphogenetic proteins induce pancreatic cancer cell invasiveness through a Smad1-dependent mechanism that involves matrix metalloproteinase-2. Carcinogenesis 2009, 30:238-248.
29. Bardeesy N., Cheng K., Berger J., Chu G., Pahler J., Olson P., Hezel A., Horner J., Lauwers G., Hanahan D., DePinho R. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev. 2006, 20:3130-3146.
30. Hamada S., Satoh K., Hirota M., Kimura K., Kanno A., Masamune A., Shimosegawa T. Bone morphogenetic protein 4 induces epithelial-mesenchymal transition through MSX2 induction on pancreatic cancer cell line. J. Cell. Physiol. 2007, 213:768-774.
31. Alarmo E.-L., Kuukasjarvi T., Karhu R., Kallioniemi A. A comprehensive expression survey of bone morphogenetic proteins in breast cancer highlights the importance of BMP4 and BMP7. Breast Cancer Res. Treat. 2007, 103:239-246.
32. Parssinen J., Kuukasjarvi T., Karhu R., Kallioniemi A. High-level amplification at 17q23 leads to coordinated overexpression of multiple adjacent genes in breast cancer. Br. J. Cancer 2007, 96:1258-1264.
33. Parssinen J., Alarmo E.-L., Karhu R., Kallioniemi A. PPM1D silencing by RNA interference inhibits proliferation and induces apoptosis in breast cancer cell lines with wild-type p53. Cancer Genet. Cytogenet. 2008, 182:33-39.
34. Rasband W.S. ImageJ 1997-2009, U.S. National Institutes of Health, Bethesda, Maryland, USA. http://rsb.info.nih.gov/ij/.
35. Ketolainen J.M., Alarmo E.-L., Tuominen V.J., Kallioniemi A. Parallel inhibition of cell growth and induction of cell migration and invasion in breast cancer cells by bone morphogenetic protein 4. Breast Cancer Res. Treat. 2010, 124:377-386.
36. Kim I., Lee D., Ahn H., Tokunaga H., Song W., Devereaux L., Jin D., Sampath T., Morton R. Expression of bone morphogenetic protein receptors type-IA, -IB and -II correlates with tumor grade in human prostate cancer tissues. Cancer Res. 2000, 60:2840-2844.
37. Henderson L.J., Coe B.P., Lee E.H., Girard L., Gazdar A.F., Minna J.D., Lam S., MacAulay C., Lam W.L. Genomic and gene expression profiling of minute alterations of chromosome arm 1p in small-cell lung carcinoma cells. Br. J. Cancer 2005, 92:1553-1560.
38. Jin Y., Tipoe G.L., Liong E.C., Lau T.Y., Fung P.C., Leung K.M. Overexpression of BMP-2/4, -5 and BMPR-IA associated with malignancy of oral epithelium. Oral Oncol. 2001, 37:225-233.
39. Johnsen I.K., Kappler R., Auernhammer C.J., Beuschlein F. Bone morphogenetic proteins 2 and 5 are down-regulated in adrenocortical carcinoma and modulate adrenal cell proliferation and steroidogenesis. Cancer Res. 2009, 69:5784-5792.
40. Rothhammer T., Bataille F., Spruss T., Eissner G., Bosserhoff A.K. Functional implication of BMP4 expression on angiogenesis in malignant melanoma. Oncogene 2007, 26:4158-4170.
41. Deng H., Makizumi R., Ravikumar T.S., Dong H., Yang W., Yang W.L. Bone morphogenetic protein-4 is overexpressed in colonic adenocarcinomas and promotes migration and invasion of HCT116 cells. Exp. Cell Res. 2007, 313:1033-1044.
42. Deer E.L., Gonzalez-Hernandez J., Coursen J.D., Shea J.E., Ngatia J., Scaife C.L., Firpo M.A., Mulvihill S.J. Phenotype and genotype of pancreatic cancer cell lines. Pancreas 2010, 39:425-435.
43. Moore P.S., Sipos B., Orlandini S., Sorio C., Real F.X., Lemoine N.R., Gress T., Bassi C., Kloppel G., Kalthoff H., Ungefroren H., Lohr M., Scarpa A. Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch. 2001, 439:798-802.
44. Buckley S., Shi W., Driscoll B., Ferrario A., Anderson K., Warburton D. BMP4 signaling induces senescence and modulates the oncogenic phenotype of A549 lung adenocarcinoma cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2004, 286:L81-L86.
45. Piccirillo S., Reynolds B., Zanetti N., Lamorte G., Binda E., Broggi G., Brem H., Olivi A., Dimeco F., Vescovi A. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006, 444:761-765.
46. Ro T.B., Holt R.U., Brenne A.T., Hjorth-Hansen H., Waage A., Hjertner O., Sundan A., Borset M. Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells. Oncogene 2004, 23:3024-3032.
47. Massagué J., Gomis R. The logic of TGFbeta signaling. FEBS Lett. 2006, 580:2811-2820.
48. Anjomshoaa A., Nasri S., Humar B., McCall J.L., Chatterjee A., Yoon H.S., McNoe L., Black M.A., Reeve A.E. Slow proliferation as a biological feature of colorectal cancer metastasis. Br. J. Cancer 2009, 101:822-828.
49. Morrissey C., Brown L.G., Pitts T.E., Vessella R.L., Corey E. Bone morphogenetic protein 7 is expressed in prostate cancer metastases and its effects on prostate tumor cells depend on cell phenotype and the tumor microenvironment. Neoplasia 2010, 12:192-205.